{"id":111998,"date":"2024-03-27T11:39:39","date_gmt":"2024-03-27T06:09:39","guid":{"rendered":"http:\/\/finservwealth.com\/astrazeneca-pharma-rises-4-on-getting-cdsco-nod-to-import-cancer-treatment-drug\/"},"modified":"2024-03-27T11:39:39","modified_gmt":"2024-03-27T06:09:39","slug":"astrazeneca-pharma-rises-4-on-getting-cdsco-nod-to-import-cancer-treatment-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/astrazeneca-pharma-rises-4-on-getting-cdsco-nod-to-import-cancer-treatment-drug\/","title":{"rendered":"AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug"},"content":{"rendered":"<p> AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.<\/p><div id=\"finse-613960326\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/astrazeneca-pharma-rises-4getting-cdsco-nod-to-import-cancer-treatment-drug_17507271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period. AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/astrazeneca-pharma-rises-4getting-cdsco-nod-to-import-cancer-treatment-drug_17507271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/astrazeneca-pharma-rises-4getting-cdsco-nod-to-import-cancer-treatment-drug_17507271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period. AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/astrazeneca-pharma-rises-4getting-cdsco-nod-to-import-cancer-treatment-drug_17507271.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-111998","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/A\/Astrazeneca_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/111998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=111998"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/111998\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=111998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=111998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=111998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}